All In MedTech

Device Trial Radar · NCT05985304

Clinical Trial of a Hydrophilic EMV Toric Lens RAO210T in the Correction of Aphakia and Corneal Astigmatism

Clinical Trial to Investigate the Safety and Effectiveness of a Hydrophilic EMV Toric Lens RAO210T in the Correction of Aphakia and Post-operative Corneal Astigmatism

Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 274 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

274

Actual

Start

Aug 10, 2023

Primary completion

Oct 23, 2024

Study completion Oct 23, 2024

Sponsor

Lead sponsor
Rayner Intraocular Lenses LimitedNot on our public-company list
Sponsor type
Industry
First posted
Aug 14, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of the clinical investigation are to determine the safety and performance of the RayOne EMV Toric (Model RAO210T) following unilateral implantation and approximately 6 months (120 to 180 days) of post-operative assessment, as a randomized comparison to aspheric monofocal control for low cylinder (1.50 D). This patient population with cataracts and low corneal cylinder (+1.00 to +1.50 D) will have the natural crystalline lens removed and replaced with an intraocular lens in the capsular bag.

Conditions

  • Cataract
  • Corneal Astigmatism

Interventions

  • RayOne EMV Toric IOLDevice

    Implantation of intraocular lens.

  • RayOne Monofocal IOLDevice

    Implantation of intraocular lens.

  • Cataract SurgeryProcedure

    Removal of natural crystalline lens due to cataracts

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Magnitude of Residual Manifest CylinderTime frame: 120 to 180 days post-operatively

8 more outcomes with a free account

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Vold Vision

    Fayetteville, Arkansas

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.